Moderna Inc. ($MRNA) Stock Forecast: Up 5.3% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company known for its innovative mRNA technology, particularly in the development of vaccines and therapies.

Why is Moderna Inc. going up?

MRNA stock is up 5.3% on Oct 15, 2025 16:26

• Moderna's stock (MRNA) demonstrated strong bullish movement today, surpassing the market performance.
• Positive response rates for its skin cancer combo therapy and encouraging early data for its investigational cancer antigen therapy presented at the 2025 European Society for Medical Oncology Congress likely influenced the bullish trend.
• Investor optimism regarding Moderna's progress in cancer treatment is fueling the increase in stock price, with expectations of future growth in this sector.
• The company's track record of innovation and promising results in the oncology field is attracting investor attention and bolstering confidence in Moderna's long-term prospects, evident in the stock's upward trajectory.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna ( MRNA ) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.

https://www.zacks.com/stock/news/2768741/moderna-mrna-registers-a-bigger-fall-than-the-market-important-facts-to-note

Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients - Moderna ( NASDAQ:MRNA )

Moderna Inc. ( NASDAQ:MRNA ) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkpoint inhibitor-resistant/refractory ( CPI-R/R ) melanoma will be presented at the 2025 ...

https://www.benzinga.com/news/health-care/25/10/48177837/moderna-reports-promising-response-rates-for-skin-cancer-combo-therapy-in-resistant-patients

Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress

mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial

https://markets.businessinsider.com/news/stocks/moderna-presents-promising-early-data-for-its-investigational-cancer-antigen-therapy-at-the-2025-european-society-for-medical-oncology-congress-1035328617

Moderna ( MRNA ) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Moderna (MRNA) stood at $27.92, denoting a +2.12% move from the preceding trading day.

https://www.zacks.com/stock/news/2764921/moderna-mrna-surpasses-market-returns-some-facts-worth-knowing

Trending Today

StoneCo Ltd. ($STNE) Stock Forecast: Up 5.1% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 5.1% Today

Abbott Laboratories ($ABT) Stock Forecast: Down 4.8% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.9% Today

NASDAQ-100 ($NDX) Index Forecast: Down 1.0% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Down 5.1% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 5.4% Today

Prologis Inc. ($PLD) Stock Forecast: Up 6.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 5.3% Today

Chainlink ($LINK) Crypto Forecast: Down 5.0% Today

Moderna Inc. Price History

18.08.2025 - MRNA Stock was up 5.1%

• MRNA stock demonstrated a notable upward trend today.
• Encouraging initial data for Moderna's revised 2025-2026 Spikevax variant, highlighting a substantial rise in neutralizing antibodies against the LP.8.1 COVID-19 strain, contributed to investor confidence.
• The vaccine's continued effectiveness against prominent COVID strains and the absence of new safety issues bolstered positive outlook.
• While Moderna received favorable updates, the wider COVID-19 vaccine industry faced some strain on concerns relating to child fatalities connected to vaccinations, impacting various stocks including MRNA, BNTX, PFE, and NVAX.

25.08.2025 - MRNA Stock was down 5.1%

• Positive preliminary data regarding the immunogenicity of Moderna's updated COVID-19 vaccine formula was recently shared. This information may have raised concerns about the current vaccine's efficacy, prompting profit-taking by investors.
• Although the overall stock market saw gains, investors possibly shifted their funds from Moderna to other more promising opportunities. This movement contributed to a decline in MRNA stock.
• In the previous trading session, Moderna's stock price experienced a +2.03% shift, setting high expectations among investors. However, a sell-off occurred as the new vaccine update fell short of these expectations, resulting in the bearish movement.

22.08.2025 - MRNA Stock was up 5.7%

• Moderna's stock saw an upward trend today following the promising release of data on its updated 2025-2026 Spikevax formula. The data indicated a significant boost in neutralizing antibodies against the LP.8.1 COVID-19 variant.
• The announcement of an impressive over 8-fold rise in antibodies for the updated Spikevax version, especially among older individuals and those with pre-existing medical conditions, influenced investors positively, leading to a surge in the stock price.
• The continuous stream of encouraging reports on Moderna's vaccine effectiveness and safety record, coupled with the absence of any new safety issues, has bolstered confidence in the market, attracting increased investor interest in the stock.
• In summary, Moderna's robust performance today mirrors the market's optimistic outlook on the company's contributions to fighting COVID-19 and developing efficient vaccine solutions.

16.08.2025 - MRNA Stock was up 9.2%

• Moderna's stock (MRNA) experienced a strong bullish movement today.
• The positive news of Moderna reporting an 8-fold increase in antibodies with its updated Spikevax vaccine for adults 65+ and those with underlying conditions likely contributed to the bullish trend.
• Despite the negative reports linking COVID-19 vaccines to child deaths and the decline in Moderna's stock price in the past, the recent positive data on vaccine efficacy and safety seems to have overshadowed these concerns, driving the stock higher.
• Investors are likely reacting favorably to the news of Moderna's vaccine effectiveness against top COVID strains, which could potentially lead to increased demand and revenue for the company in the future.

16.08.2025 - MRNA Stock was up 5.1%

• Despite recent concerns about COVID-19 vaccine safety and a decrease in Moderna's stock price, MRNA showed strong bullish movement today.
• Investor focus may be centered on the company's positive long-term prospects and vaccine portfolio rather than short-term events.
• Market dynamics could be shaped by various factors such as favorable clinical trial outcomes, regulatory nods, and investor sentiment towards the biotech industry.
• The uptick in MRNA's performance today could be attributed to investors viewing the recent stock price decline as an opportunity to buy, with expectations of the company's future growth and accomplishments.

08.09.2025 - MRNA Stock was up 6.1%

• Moderna's stock price surged by +2.83% following positive sentiment in the pharmaceutical sector and a general uptrend in the market.
• The anticipation of up to 10 new product launches over the next four years has likely boosted investor confidence, signaling a potential diversification away from reliance on COVID-19 vaccine sales.
• Breaking above the 50-day moving average is seen as a bullish signal, indicating potential further upside for the stock.
• The overall market optimism, coupled with Moderna's strategic moves towards product diversification, has contributed to the bullish movement in MRNA stock today.

09.09.2025 - MRNA Stock was down 5.6%

• Despite recent developments, Moderna's stock experienced a bearish movement today.
• The discrepancy between noteworthy developments and the stock's movement could be attributed to profit-taking by investors.
• Market sentiment or broader economic factors may have affected Moderna's stock performance, overshadowing recent positive news.
• Investors should consider both company-specific updates and market conditions when trading Moderna's stock.

26.08.2025 - MRNA Stock was down 5.2%

• Moderna's stock faced a more significant decline compared to the broader market, signaling a pessimistic outlook among investors.
• While the company disclosed encouraging initial data on the effectiveness of its COVID-19 vaccine against the LP.8.1 variant, external factors such as market conditions or profit realization might have contributed to the negative response.
• The decline of -4.91% in Moderna's stock price could also be attributed to profit-taking following a period of sustained growth, with investors opting to capitalize on their profits.

15.09.2025 - MRNA Stock was up 5.3%

• Moderna's stock (MRNA) demonstrated strong bullish movement today, surpassing the market performance.
• Positive response rates for its skin cancer combo therapy and encouraging early data for its investigational cancer antigen therapy presented at the 2025 European Society for Medical Oncology Congress likely influenced the bullish trend.
• Investor optimism regarding Moderna's progress in cancer treatment is fueling the increase in stock price, with expectations of future growth in this sector.
• The company's track record of innovation and promising results in the oncology field is attracting investor attention and bolstering confidence in Moderna's long-term prospects, evident in the stock's upward trajectory.

25.07.2025 - MRNA Stock was down 5.0%

• Today's decline in Moderna's stock price could be linked to concerns regarding the Trump administration's contemplation of removing COVID-19 vaccines from the market. This uncertainty may have prompted investors to sell, influenced by the unsettling news.
• The approval of Moderna's updated Spikevax vaccine by Health Canada could have been viewed positively. Despite this, the broader market sentiment, undulated by negative reports, overshadowed this favorable development.
• The ambiguity and contradictory information about the future of COVID-19 vaccines and their potential impact on Moderna's market position likely contributed to the bearish trend in the stock today.
• Investors are likely keeping a close watch on any updates regarding vaccine regulations and approvals, as well as Moderna's strategies to navigate the evolving dynamics of the healthcare sector.

01.09.2025 - MRNA Stock was up 8.2%

• Moderna stock surged today, likely driven by the positive sentiment in the pharmaceutical sector following a landmark agreement between another company and the Trump administration to lower prescription drug prices.
• Despite a recent dip in the stock price, the overall bullish movement today indicates that investors are optimistic about Moderna's future prospects and its role in the healthcare industry.
• The positive market response suggests that investors view Moderna as a key player in the development of innovative medical solutions, particularly in the context of the ongoing global health crisis.

14.09.2025 - MRNA Stock was down 5.7%

• Promising early data for Moderna's investigational cancer antigen therapy, mRNA-4359, was presented at a medical oncology congress, suggesting potential progress in cancer treatment.
• Despite advancements in cancer therapies, Moderna's stock saw a decline, possibly attributed to profit-taking following recent gains or shifts in market sentiment.
• The market's reaction to the data presentation may have been negative, with expectations for more immediate commercialization or revenue impact not being met, contributing to the stock's bearish movement.